We estimated the rate of reactivation tuberculosis (TB) in the United States, overall and by population subgroup, using data on TB cases and Mycobacterium tuberculosis isolate genotyping reported to the Centers for Disease Control and Prevention during [2006][2007][2008]. The rate of reactivation TB was defined as the number of non-genotypically clustered TB cases divided by the number of person-years at risk for reactivation due to prevalent latent TB infection (LTBI). LTBI was ascertained from tuberculin skin tests given during the 1999-2000 National Health and Nutrition Examination Survey. Clustering of TB cases was determined using TB genotyping data collected by the Centers for Disease Control and Prevention and analyzed via spatial scan statistic. Of the 39,920 TB cases reported during [2006][2007][2008] 79.7% were attributed to reactivation. The overall rate of reactivation TB among persons with LTBI was estimated as 0.084 (95% confidence interval (CI): 0.083, 0.085) cases per 100 personyears. Rates among persons with and without human immunodeficiency virus coinfection were 1.82 (95% CI: 1.74, 1.89) and 0.073 (95% CI: 0.070, 0.075) cases per 100 person-years, respectively. The rate of reactivation TB among persons with LTBI was higher among foreign-born persons (0.098 cases/100 person-years; 95% CI: 0.096, 0.10) than among persons born in the United States (0.082 cases/100 person-years; 95% CI: 0.080, 0.083). Differences in rates of TB reactivation across subgroups support current recommendations for targeted testing and treatment of LTBI.
Despite substantial declines in the incidence of tuberculosis (TB) in the United States since 1993, more than 10,000 cases continue to occur each year (1) . These cases may result from recent transmission of Mycobacterium tuberculosis or from reactivation of latent TB infection (LTBI), known as reactivation TB. Molecular epidemiologic studies carried out in some areas of the United States suggest that the decline in TB incidence in these areas has been associated with an increased proportion of cases occurring from reactivation of LTBI (2) (3) (4) , and an analysis of US TB cases identified during [2005] [2006] [2007] [2008] [2009] indicated that nearly 77% of TB cases may be attributable to reactivation (5) . Therefore, to continue to reduce TB incidence in the United States, it is important to understand which subgroups of the general population have the highest rates of progression from LTBI to active TB disease.
Some risk factors for reactivation TB have already been established. Human immunodeficiency virus (HIV)-infected persons progress from LTBI to active TB disease at 9 times the rate of HIV-uninfected persons (6) . To a lesser extent, other medical risk factors, such as old healed TB disease, chronic renal failure, poorly controlled diabetes, or use of tumor necrosis factor-α-inhibitor therapy, also increase the risk of progression from LTBI to active TB (6) . However, these conditions are relatively rare in the general population and are unlikely to account for the majority of reactivation TB cases.
Although some reports have suggested that foreign-born persons in the United States are more likely to have reactivation TB than US-born persons, it is unclear whether higher reactivation among foreign-born persons reflects a higher prevalence of LTBI in this population or an increased rate of progression from LTBI to TB disease, or both (5) . In a southeastern US study that examined the rate of reactivation TB among persons with LTBI, Horsburgh et al. (7) concluded that increased progression from LTBI to active TB disease was associated with older age and foreign birth, but it is not clear whether this finding can be generalized to the entire US population. Since a substantial proportion of TB reported in the United States arises from older and foreignborn persons (1) , it is important to determine whether the rate of progression from LTBI to TB disease is higher in these groups.
Conducting a cohort study is not practical for measuring the rate of reactivation TB among persons with LTBI in the United States, because TB occurs infrequently and because LTBI treatment, which is offered routinely, further decreases the rate of reactivation. However, we were able to estimate rates of reactivation TB by first using 2006-2008 genotyping and epidemiologic linkage information from the National Tuberculosis Genotyping Service to differentiate between cases of presumed primary TB and cases of reactivation TB. Next, we used population-based tuberculin skin testing (TST) results from the 1999-2000 National Health and Nutrition Examination Survey (NHANES) to estimate the number of US residents with LTBI, who were thus at risk for reactivation TB. Since prevention of reactivation TB by treatment of LTBI is a major goal of the US national strategy for TB elimination (6) , identification of population subgroups with LTBI who are at increased risk of reactivation TB will help in targeting intervention strategies.
MATERIALS AND METHODS

Identification of clustered cases of TB
The Centers for Disease Control and Prevention (CDC) has collected information on newly reported cases of TB disease in the United States since 1953. Cases are currently reported to the National Tuberculosis Surveillance System using a standard case report form and a specified TB case definition for laboratory and clinical criteria (1) . The National Tuberculosis Genotyping Service was established in 2004 with the goal of using standard genotyping methods to genotype at least 1 M. tuberculosis isolate from each cultureconfirmed TB case reported in the United States (8) (9) (10) . Overall national genotyping surveillance coverage, defined as the proportion of reported culture-positive TB cases with a genotype result, was 66% in 2006 and approximately 80% in 2007 and 2008 (9) .
TB cases reported to the National Tuberculosis Surveillance System during 2006-2008 were used in the current study and were linked to genotyping results from the National Tuberculosis Genotyping Service using a standard protocol (9) . All TB cases that were not part of a genotype cluster, as defined below, were considered cases of reactivation TB. The underlying assumption for this approach is that TB cases connected by recent transmission should have indistinguishable genotypes and should occur within the same local jurisdiction as another genotypically related case. Conversely, cases due to reactivation of LTBI are expected to have unique genotypes unrelated to other cases identified within the past few years and within the same local jurisdiction (11) . TB clusters were identified using methods previously described by Moonan et al. (11) , with the exception that we used a single 3-year period in the current project. Briefly, TB genotypes were characterized using a standardized protocol for spacer oligonucleotide typing (spoligotyping) and 12-locus mycobacterial interspersed repetitive unit-variable number of tandem repeats (MIRU-VNTR) typing. Genotype clusters were defined as at least 2 cases with indistinguishable TB genotypes reported within statistically significant geospatial zones as determined by a spatial scan statistic (SaTScan, Martin Kulldorff, Boston, Massachusetts; and Information 
Identification of populations with LTBI
Because there are no data describing the prevalence of LTBI in the United States during 2006-2008, the prevalence of LTBI in the United States was estimated using TST results collected in the 1999-2000 NHANES, a series of crosssectional health examination surveys representative of the civilian noninstitutionalized US population. NHANES survey methodology has been previously described in detail (13) .
NHANES survey data collected during 1999-2000 include demographic and TST results for 7,386 participants aged 1 year or older in whom TST was performed via the Mantoux technique using 0.1 mL of purified protein derivative S-1, the reference standard tuberculin used in the United States (14) . The tests were administered by trained NHANES phlebotomists and read by trained NHANES TST readers 48-72 hours after placement (15) .
NHANES participants with an induration of 10 mm or greater were classified as having LTBI, regardless of HIV infection status (because HIV status was unknown for NHANES participants). SAS software, version 9.2 (SAS Institute Inc., Cary, North Carolina), was then used to account for the NHANES sample design and weighting through application of methods described by Bennett et al. 
Estimation of rates of reactivation TB
The rate of reactivation TB was calculated by dividing the number of nonclustered TB cases by the number of person- b Comparison of genotyped cases with nongenotyped cases revealed that genotyped cases were more likely to be male, to reside in the western region of the United States, and to have been born outside of the United States; genotyped and nongenotyped cases also differed by age group and race/ethnicity (P < 0.001 for all χ (17), and unadjusted rate ratios and 95% confidence intervals were calculated using SAS. Reactivation rates were calculated both by the "n" method, in which all nonclustered cases of TB were used in the numerator, and by the "n − 1" method, in which the first reported case in each cluster was assumed to be due to reactivation and was therefore reclassified as nonclustered. Because the results from both methods were consistent, only results from the "n" method are presented.
Estimation of rates among HIV-infected persons
Because HIV-infected persons with LTBI have a much higher risk of developing active TB than HIV-uninfected persons, we estimated the rate of reactivation TB separately for HIV-infected and HIV-uninfected US residents. For reported TB cases aged 15-64 years with an unknown HIV infection status, we used Markov chain Monte Carlo multiple-imputation methods to assign HIV infection status based on an imputation model that used the characteristics of patients with known HIV status for each stratum. California was excluded from this analysis because the HIV status of TB cases reported in California was not reported to the CDC during 2006-2008. Next, because NHANES did not include information about HIV status and because the proportion of HIV-infected persons in the United States who have LTBI is unknown, we assumed that LTBI prevalence in HIVinfected persons was the same as the prevalence of LTBI in the US population (Appendix).
Ethical review
This project analyzed data collected for the purposes of routine disease surveillance and disease control and was (Table 2) ; however, except for pediatric cases, in which the majority of TB diagnoses are based on a clinical case definition, the distribution of genotyped and nongenotyped cases generally differed by 5% or less.
Among the 22,857 TB cases with genotypes, 18,308 (80.1%) were not part of a genotype cluster and were attributed to LTBI reactivation. The percentage of TB cases attributed to reactivation differed for US-born (11,672 cases; 70.1%) and foreign-born (20,046 cases; 86.5%) persons. Applying risk-group-specific percentages of nonclustered cases to the number of risk-group-specific TB cases that could not be genotyped yielded an additional 5,274 and 8,173 cases of reactivation TB in US-born and foreign-born persons, respectively. The prevalence of LTBI based on NHANES data was found to vary by sex, age, race/ethnicity, US Census region, and country of birth (Table 3) .
Rates of reactivation TB
The overall rate of reactivation TB among US residents with LTBI was estimated to be 0.084 cases per 100 personyears (95% confidence interval (CI): 0.083, 0.085). Table 3 presents the overall rate of reactivation TB stratified by sex, age group, race/ethnicity, and US Census region. Because the rate of reactivation TB among persons with LTBI was significantly higher among foreign-born persons (0.098 cases/ 100 person-years; 95% CI: 0.096, 0.10) than among USborn persons (0.082 cases/100 person-years; 95% CI: 0.080, 0.083), we further stratified rates by birthplace (Table 4) .
Estimated rates in HIV-infected residents
Among patients aged 15-64 years not residing in California, there were 10,997 genotyped cases and an estimated 7,769 nongenotyped cases of reactivation TB during 2006-2008. Among the 10,997 genotyped cases, HIV infection status was positive in 8.9%, negative in 77.1%, and unknown in 14.0%. Imputation indicated that 10.0% of genotyped patients with reactivation TB and 14.1% of nongenotyped patients with reactivation TB were HIV-infected, yielding an estimate of 2,198 HIV-infected cases of reactivation TB. Therefore, the US rate of reactivation TB among HIVinfected persons was estimated to be 1.82 cases per 100 person-years, assuming a 4.2% prevalence of LTBI in the HIV-infected population (Table 5) .
DISCUSSION
We observed an overall rate of reactivation TB among persons with LTBI in the United States of approximately 0.084 cases per 100 person-years. This rate is substantially lower than the rates of 0.10-0.16 per 100 person-years observed in the 1950s (6) but higher than the rate of 0.040 observed in a recent population-based study in southern Florida (7) . The decline in this rate in the United States over the past 5 decades probably represents elimination of a common highrisk subgroup from the population, namely persons with old, healed but untreated TB disease. These persons are known to have 5 times the reactivation rate of persons with LTBI without old, untreated disease, and such cases are much less common today than in the early chemotherapy era (7). The lower rates reported from the southern Florida study may reflect geographical variability that is partially explained by the high prevalence of infection with non-TB mycobacteria in that region, which can yield a positive test result even when M. tuberculosis is not present (18) . Such crossreactivity artificially increases the size of the population "at risk" (since persons with a cross-reactive TST test are "false-positive" for LTBI) and decreases the calculated reactivation rate.
The overall rate of reactivation was also substantially different between US-born (0.082 cases/100 person-years) and foreign-born (0.098 cases/100 person-years) persons. This difference is consistent with what has been observed in other studies (3, 5) and is probably the result of a higher prevalence of risk factors for reactivation, such as old, healed disease, poor nutrition or other immunosuppressive states, or more recent infection, among foreign-born persons. Unfortunately, we did not have individual-level information on these variables for the TST survey, so we could not adjust for these potential cofounders.
However, our results differ from those of a case-control analysis comparing 188 case-patients with 188 matched controls in Boston, Massachusetts, that did not find an increased rate of reactivation among foreign-born persons (19) . That analysis differed from ours in terms of study design, population, and sample size. In addition, it is possible that some foreign-born persons with TB, particularly those who have recently arrived in the United States, may be misclassified as having unclustered (reactivation) TB because the related cases of that genotype are outside the geographical limit for clustering (20, 21) , or that the population of foreign-born persons living in the United States was underestimated in the US Census.
Among US-born persons with LTBI, we observed increased rates of reactivation at both ends of the age spectrum. Young children are known to be at increased risk of reactivation (22) , a phenomenon thought to be explained by the immaturity of their immune systems. Older persons are known to have a higher prevalence of reactivation TB, but this has largely been attributed to the higher prevalence of LTBI in the elderly. Our results show that among US-born persons, rates of progression from LTBI to TB disease decline with age. This is consistent with the observations of a recent cohort study in Norway (23) .
Among foreign-born persons with LTBI, we observed a low rate of reactivation among young children and increased rates of reactivation with increasing age. A possible reason for lower reactivation among young children could be overestimation of LTBI in this population due to recent Bacillus Calmette-Guérin vaccination, whereas the increased rate in the oldest age group may be due to recent infections among some foreign-born elderly persons who had recently arrived in the United States.
There was also substantial variability of reactivation rates among racial/ethnic groups: Asians and Hispanics had elevated rates of reactivation compared with non-Hispanic whites among both US-born and foreign-born persons, and foreign-born blacks had elevated rates compared with foreignborn whites. This may be attributable to increased prevalence of old, healed disease, since these subgroups may have had decreased access to TB diagnosis and treatment. Additionally, some of these groups, particularly blacks and Hispanics, may have increased prevalence of HIV infection that was not accounted for in our study.
This analysis had several important limitations. First, there was potential for misclassification of cases of reactivation TB. We used lack of clustering as a proxy for reactivation TB, but there are circumstances in which recently transmitted TB cases may not cluster, such as when related cases are outside the geographical or temporal frame of the analysis. For example, we may have attributed some cases to reactivation because other cases with related genotypes were outside of our 3-year study period. In addition, partial sampling of genotypes may have led to overascertainment of reactivation cases if related cases were not detected because of missing genotyping results. Next, although TB clustering status was determined from all cases reported to the National Tuberculosis Genotyping Service, isolate submission is incomplete and imputation of results from cases without genotyping may have introduced bias. Genotype coverage was consistent for sex, age group, and race/ethnicity subpopulations but was lower in the Northeast in 2006 (45%) as compared with other years and other regions (60%-80%). This may have resulted in overestimation of the rate of reactivation TB in the Northeast due to not having sufficient coverage to identify clusters. In addition, because we performed a large number of SaTScan runs for hundreds of different genotypes, it is possible that we overestimated the number of statistically significant clusters. This would mean that the reactivation rate we observed was an underestimate of the true rate.
Second, misclassification of LTBI also may have occurred. LTBI prevalence estimated during the 1999-2000 NHANES was probably slightly higher than LTBI prevalence during 2006-2008 (24) , producing potential overestimation of rates in our study. However, we do not have reason to expect that our ratio measures comparing population subgroups would have been substantially affected. Misclassification of LTBI status also may have occurred because TST results were interpreted without regard to skin tests for non-TB mycobacteria or prior Bacillus Calmette-Guérin vaccination.
Third, although we were able to calculate the rate of reactivation TB by age group, waning TST reactivity in the elderly might mean that the true rate was even lower than what we observed.
Lastly, we did not have sufficient information in our data set to estimate the amount of reactivation separately for persons with and without diabetes, and our analysis of the amount of reactivation that can be attributed to HIV infection required substantial imputation. In our HIV imputation, we used a range of assumptions, all of which led to the same conclusion-namely that although the effect of HIV on reactivation was large, the effect of HIV on overall rates in the United States was small because of small numbers of HIV-infected persons in the population.
Targeted testing for and treatment of LTBI is a key strategy for elimination of TB in the United States, and the results of this analysis have important implications for the design and implementation of such programs, as well as for costeffectiveness analyses. A recent study demonstrated that targeting specific populations for screening and treatment was highly cost-effective (25) . However, that study assumed that the reactivation rate was constant among all populations. Our results indicate that certain groups, especially the foreignborn and racial and ethnic minorities, have increased rates of progression and will receive even greater benefit from testing and treatment. Conversely, persons in certain geographical areas may have lower rates of progression and may receive less benefit. Since these lower rates may be at least partially attributable to misclassification of LTBI status by skin testing, greater use of interferon-γ release assays for identification of LTBI may remove this source of misclassification. These results reinforce recent recommendations for targeted testing and treatment of LTBI as a cost-effective intervention, especially among foreign-born persons (25) . 
